FDA panel votes no on using MDMA for PTSD treatment: a loss for supporters of psychedelic therapy.

An FDA panel met to discuss the use of MDMA, also known as ecstasy, as a treatment for PTSD. The panel voted against recommending MDMA for PTSD treatment, citing concerns about the research.

The panel had several concerns, including flawed study data, potential for drug abuse, and lack of diversity among participants. They also questioned the reliability of the results due to patients being able to guess if they received MDMA or a placebo.

Additional concerns were raised about reports of misconduct during the trials, including an allegation of sexual misconduct by a therapist. Lykos Therapeutics, the company behind the study, stated they would address the panel's concerns.

Despite the negative vote, some experts still see potential in using psychedelics like MDMA for PTSD treatment. They urged continued research in the field, emphasizing the need for more robust data on safety and efficacy.

The FDA is not obligated to follow the panel's recommendation and will make a final decision by August. This decision holds significant weight for the future of psychedelic treatments and the companies investing in them.